What does Section IV.3 of the 2025 OECD Merger Review Recommendation establish as the hierarchy for acceptable remedies in merger proceedings, and what is the priority ordering within the structural remedies tier?
Section IV.3 establishes a two-level preference: structural over behavioural, and standalone-business divestiture as the preferred structural form. The model elaborated this into a three-tier internal ranking, upfront/fix-it-first divestiture, buyer pool with trustee backstop, crown jewel packages, that maps onto common EU and US merger remedy practice but does not appear in the 2025 OECD Recommendation's text. The model substituted a practitioner-familiar remedy taxonomy drawn from other jurisdictions' frameworks for the Recommendation's simpler, less-prescriptive hierarchy, and presented the elaborated ranking as the OECD standard.
The three-tier internal remedy ranking the model produced maps precisely onto EU Merger Regulation remedy practice and US DOJ/FTC remedy convention — frameworks heavily represented in training. The OECD Recommendation's simpler two-level preference appears insufficiently weighted to override the more detailed framework when both are plausibly relevant. This implicates retrieval ranking (primary text vs. adjacent-jurisdiction commentary) and calibration (schema-elaboration confidence when the retrieved content does not support the elaboration).
When Legal teams at Pharmaceuticals firms ask AI tools to summarise the internal priority ordering within structural remedies under the OECD Recommendation, AI assistants we tested returned a three-tier hierarchy, fix-it-first divestitures, then commitments backed by an approved buyer pool and trustee mandate, then crown jewel or ring-fenced packages, sourced from EU merger-control enforcement practice rather than from the Recommendation itself. The Recommendation's Section IV.3 establishes a single preference: standalone-business divestitures are prioritised within the structural tier, with no timing-based sub-ordering.
A deal playbook, board paper, or internal guidance document built on the AI's version misrepresents the applicable multilateral standard and potentially mis-scopes the firm's remedy posture across every OECD-member-state filing where that document serves as the reference. The downstream cost is not regulatory penalty but mispriced deal risk: a remedy package designed around the wrong framework may require mid-negotiation restructuring, extending transaction timelines and increasing external counsel fees at the point of maximum exposure.
Each finding has a stable Citation ID (RLB-F-… for aggregated case-study findings, RLB-H-… for raw per-model hallucinations) — like a DOI, the ID always resolves to the canonical finding even if URLs change.
RegLeg Specialist Panel (2026). "Finding#1, Section IV.3 structural remedy priority order misattributed to EU practice — Pharmaceuticals × Legal — International / Multilateral." Citation ID: RLB-F-INT-OECD-OECD-MERGER-REVIEW-RECOMMENDATION-2025-Q002. RegLegBrief AI Hallucination Research, published 2026-06-11. https://reglegbrief.com/regulators/j1/int/OECD/OECD-MERGER-REVIEW-RECOMMENDATION-2025/sectors/pharmaceuticals/legal/finding/INT-OECD-INT-001-OECD-MERGER-REVIEW-RECOMMENDATION-2025-v1-002/
RegLeg Specialist Panel. (2026). Finding#1, Section IV.3 structural remedy priority order misattributed to EU practice [Hallucination finding RLB-F-INT-OECD-OECD-MERGER-REVIEW-RECOMMENDATION-2025-Q002]. RegLegBrief AI Hallucination Research. https://reglegbrief.com/regulators/j1/int/OECD/OECD-MERGER-REVIEW-RECOMMENDATION-2025/sectors/pharmaceuticals/legal/finding/INT-OECD-INT-001-OECD-MERGER-REVIEW-RECOMMENDATION-2025-v1-002/
RegLeg Specialist Panel, Finding#1, Section IV.3 structural remedy priority order misattributed to EU practice [RLB-F-INT-OECD-OECD-MERGER-REVIEW-RECOMMENDATION-2025-Q002], RegLegBrief AI Hallucination Research (June 11, 2026), https://reglegbrief.com/regulators/j1/int/OECD/OECD-MERGER-REVIEW-RECOMMENDATION-2025/sectors/pharmaceuticals/legal/finding/INT-OECD-INT-001-OECD-MERGER-REVIEW-RECOMMENDATION-2025-v1-002/.
@misc{reglegbrief_RLB_F_INT_OECD_OECD_MERGER_REVIEW_RECOMMENDATION_2025_Q002,
author = {RegLeg Specialist Panel},
title = {Finding#1, Section IV.3 structural remedy priority order misattributed to EU practice},
year = {2026},
publisher = {RegLegBrief AI Hallucination Research},
note = {Hallucination finding Citation ID: RLB-F-INT-OECD-OECD-MERGER-REVIEW-RECOMMENDATION-2025-Q002},
url = {https://reglegbrief.com/regulators/j1/int/OECD/OECD-MERGER-REVIEW-RECOMMENDATION-2025/sectors/pharmaceuticals/legal/finding/INT-OECD-INT-001-OECD-MERGER-REVIEW-RECOMMENDATION-2025-v1-002/}
}
Every finding on this page compares an AI subject's account of the rule against the regulator's verbatim text from the regulator's own portal. Both are linked. Each delta, its root causes, and impact analysis are documented and published with immutable Citation IDs.